Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T18:32:44.310Z Has data issue: false hasContentIssue false
  • English
  • Français

Inactivation of Human Immunodeficiency Virus by Betadine

Published online by Cambridge University Press:  02 January 2015

Joan C. Kaplan ,
David C. Crawford ,
Amy G. Durno  and
Robert T. Schooley
Joan C. Kaplan*
Affiliation:
Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts
David C. Crawford
Affiliation:
Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts
Amy G. Durno
Affiliation:
Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts
Robert T. Schooley
Affiliation:
Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts
*
Infectious Disease Unit, Massachusetts General Hospital, Boston, MA 02114
Get access Rights & Permissions [Opens in a new window]

Abstract

Human immunodeficiency virus (HIV), the etiological agent of the acquired immunodeficiency syndrome (AIDS), was treated with either Betadine® (povidone-iodine) Solution or Betadine Surgical Scrub®. HIV inactivation was analyzed using the viral reverse transcriptase assay or by observing the cytopathic effect produced in HIV-infected, H-9, T-cell cultures. The minimum effective Betadine dose was 0.25% for complete inactivation of HIV that was treated for various time intervals (immediate vortex to ten minutes). The titer of HIV stocks used in these experiments (105 TCID50 per mL) was greater than amounts generally detected in clinical specimens. Our results provide a rationale for the use of povidone-iodine as a topical antiseptic against HIV in the clinic or laboratory.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 8 , Issue 10 , October 1987 , pp. 412 - 414
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Barre-Sinoussi, F, Chermann, JC, Rey, F, et al: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–871.CrossRefGoogle ScholarPubMed
2. Gallo, RC, Salahuddin, SZ, Popovic, M, et al: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500–503.Google Scholar
3. Barns, DM, Grim projections for AIDS epidemic. Science 1986;232:1589–1590.Google Scholar
4. Curran, JW, Morgan, WM, Hardy, AM, et al: The epidemiology of AIDS, Current status and future prospects. Science 1985;229:1352–1357.Google Scholar
5. Ho, DD, Schooley, RT, Rota, TR, et al: HTLV-III in the semen and blood of a healthy homosexual man. Science 1984;226:451–453.Google Scholar
6. Ho, DD, Byington, RE, Schooley, RT, et al: Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med 1985;313:1606.Google ScholarPubMed
7. Ho, DD, Rota, TR, Schooley, RT, et al: Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985;313:1493–1497.CrossRefGoogle Scholar
8. Fujikawa, LS, Salahuddin, SZ, Palestine, AG, Isolation of human T-lymphotropic virus type III from the tears of a patient with the acquired immunodeficiency syndrome. Lancet 1985;ii:529–530.CrossRefGoogle Scholar
9. Klatzmann, D, Barre-Sinoussi, F, Nugeyre, MT, et al: Selective tropism of lymph-adenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984;225:59–64.CrossRefGoogle Scholar
10. Popovic, M, Sarngadharan, MG, Read, E, et al: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497–500.CrossRefGoogle ScholarPubMed
11. Spire, B, Barre-Sinoussi, F, Montagnier, L, et al: Inactivation of lymphadenop-athy associated virus by chemical disinfectants. Lancet 1984;i:898–901.Google Scholar
12. Resnick, L, Veren, K, Salahuddin, SZ, et al: Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA 1986;225:1887–1891.Google Scholar
13. Berkelman, RL, Holland, BW, Anderson, RL, Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 1982;15:635–639.Google Scholar
14. Poiescz, BW, Ruscetti, FW, Gasdar, AF, et al: Isolation of type-C retrovirus particles from cultured human T-lymphocytic cell lines. Proc Natl Acad Sci USA 1980;77:7415–7419.CrossRefGoogle Scholar
15. Martin, LS, McDonegal, JS, Loskoski, SL, Disinfection and inactivation of the human T-lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 1985;152:400–402.CrossRefGoogle ScholarPubMed